GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Raf1 | decreases expression | EXP | | 6480464 | CTD | Arsenic Trioxide results in decreased expression of RAF1 mRNA | PMID:34037972 | Raf1 | multiple interactions | EXP | | 6480464 | CTD | Phloretin inhibits the reaction [Arsenic Trioxide results in decreased expression of RAF1 mRNA] | PMID:34037972 | Raf1 | increases expression | ISO | RAF1 (Homo sapiens) | 6480464 | CTD | Arsenic Trioxide results in increased expression of RAF1 mRNA | PMID:20458559 | Raf1 | multiple interactions | ISO | RAF1 (Homo sapiens) | 6480464 | CTD | [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of RAF1 protein modified form; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] | PMID:27794399 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |